Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1095 (LINC01095) is a member of the long intergenic non-coding RNA (lincRNA) family, which comprises autonomously transcribed RNA molecules longer than 200 nucleotides that do not overlap with protein-coding genes[1][3][6][7]. LincRNAs, including LINC01095, do not code for proteins but can exercise a range of regulatory functions such as chromatin remodeling, RNA stabilization, enhancer-like transcriptional control, and tissue-specific fine-tuning of gene expression[3][6]. While these molecules are increasingly recognized for their diverse roles in gene regulation and possibly in disease, there is no evidence that LINC01095 itself is considered a direct therapeutic target or is directly implicated in a specific disease or drug response to date[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1095 (LINC01095).